A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants

NCT04893551 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
16
Enrollment
INDUSTRY
Sponsor class

Stopped After completion of all planned dose levels in the dose escalation phase, the sponsor decision was not to continue with expanding the cohorts of any of the dose levels, using the existing study design.

Conditions

Interventions

Sponsor

BerGenBio ASA